Tiogiva (Tiotropium Bromide) inhalation powder

Tiogiva is a generic pharmaceutical product containing tiotropium, used for the long-term treatment of Chronic Obstructive Pulmonary Disease (COPD). It is developed and marketed by Glenmark Pharmaceuticals, a major global pharmaceutical company.

The brand originated in India, where Glenmark was founded and remains headquartered. While Glenmark has a significant manufacturing presence in India, it operates multiple manufacturing facilities across the globe, including sites in Europe and South America, to supply international markets like the UK and EU.

As of 2026, Glenmark remains the ultimate owner and operator of the Tiogiva brand, maintaining its status as an independent, research-led global integrated pharmaceutical company. The product is distributed through various local subsidiaries depending on the region, such as Glenmark Pharmaceuticals Europe Ltd for the UK and European markets.